China Universal Asset Management Co., Ltd. Fate Therapeutics Inc Transaction History

China Universal Asset Management Co., Ltd.

$893 Million
Q3 2024

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 May 21, 2024	BUY	$2.02 - $5.04 $2,496 - $6,229	1,236 Added 95.81%	2,526 $5,000
Q3 2023 Oct 30, 2023	BUY	$2.02 - $5.04 $2,496 - $6,229	1,236 Added 95.81%	2,526 $5,000
Q2 2023 May 21, 2024	SELL	$4.76 - $6.59 $190 - $263	-40 Reduced 3.01%	1,290 $6,000
Q2 2023 Jul 27, 2023	SELL	$4.76 - $6.59 $190 - $263	-40 Reduced 3.01%	1,290 $6,000
Q1 2023 May 21, 2024	BUY	$4.24 - $11.12 $1,454 - $3,814	343 Added 34.75%	1,330 $7,000
Q1 2023 Apr 27, 2023	BUY	$4.24 - $11.12 $1,454 - $3,814	343 Added 34.75%	1,330 $8,000
Q4 2022 May 21, 2024	BUY	$9.86 - $23.83 $9,731 - $23,520	987 New	987 $9,000
Q4 2022 Jan 31, 2023	BUY	$9.86 - $23.83 $769 - $1,858	78 Added 8.58%	987 $10,000
Q3 2022 Oct 21, 2022	BUY	$21.04 - $36.06 $19,125 - $32,778	909 New	909 $20,000

Others Institutions Holding FATE

# of Institutions

175

Shares Held

115M

Call Options Held

53.7K

Put Options Held

View Full List

About FATE THERAPEUTICS INC

Ticker FATE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,000,304
Market Cap $222M
Description
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...

More about FATE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of China Universal Asset Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on China Universal Asset Management Co., Ltd. with notifications on news.

Account